Metagenics Ultra Flora Intensive Care

Product Video

Metagenics How To Choose The Right Probiotic

Metagenics Clinical Detoxification Programs

Metagenics Gut Pathogen Elimination Program

Directions

Adults:

To rebuild healthy gut flora balance:

Take 1 capsule twice daily.

To assist gut health:

Take 1 capsule daily.

Take Metagenics Ultra Flora Intensive Care at least two hours away from antibiotics or herbal antimicrobials.

Benefits

• Rebuilds native commensal flora of the gut microbiome. Recent probiotic research¹¹ has shown that the key mechanism by which probiotics rebuild a disrupted microbiome is the modulation of native commensal bacterial populations. This is in contrast to the old understanding that probiotics repopulate by directly replacing and recolonising with specific probiotic strains and species.^12,13 The dominant bacterial families of the microbiome contain over 1000 species and many thousands of genetically unique strains to total approximately 38 trillion organisms.¹⁴
• Ultra Flora Intensive Care contains three of the world’s most widely researched probiotics (LGG®, SB and BB-12®) with documented outcomes and mechanisms for microbiome replenishment.^15,16 These genetically unique probiotics support the growth and function of the dominant bacterial groups of the microbiome^17,18 and suppress pathogen growth.¹⁹ In addition BB-12®20 and LGG® 21 strains specifically support the gut epithelial mucosa where the bacterial populations reside and interact systemically.
• Ultra Flora Intensive Care provides LGG®, SB and BB-12® strains at a clinically validated dose for microbiome restoration and to assist gastrointestinal function.^22,23,24 In addition, there is a substantial supportive body of evidence showing clinical improvement in patients with symptoms associated with microbiome depletion.^25,26,27
• Contains live, original and clinically researched probiotic forms. LGG®, SB and BB-12® are three of the world’s most extensively researched probiotics with a range of clinically demonstrated health benefits. Factors that can influence probiotic activity include its genetic profile, manufacture (from culture to production) and storage. Live SB synthesises and secretes polyamines in order to exert its beneficial effects on the gastrointestinal mucosa, and inhibits pathogens.²⁸ Ultra Flora Intensive Care guarantees live SB CFU (colony forming units) at the label dose until expiry for clinical efficacy. LGG® is a genetically unique probiotic grown to a specific culturing and manufacturing process in order to provide reproducible and consistent clinical benefits in line with its wide body of research. Probiotics are genetically unique at a strain level and health benefits are not transferrable between strains (even within species).

Ingredients

Metagenics Ultra Flora Intensive Care is free from animal products, dairy protein, lactose, eggs, gluten, wheat, nuts and soy protein. Metagenics Ultra Flora Intensive Care is free from artificial colours, flavours and preservatives.

Warnings

Not all cautions and contraindications are listed. For full details, references or more information contact HealthMasters in Australia by email: reception@healthmasters.com.au.

Always read the label. Use only as directed. If symptoms persist consult your healthcare professional.

Storage

Store at 2°C to 8°C. (Refrigerate. Do not freeze.)

References

[11] More M, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clinical and Experimental Gastroenterology. 2015;8:237-55.

[12] Horowitz S. Therapeutic Modification of the GI Microbiome. J Altern Complem Med. 2015 June;21(3):124-30.

[13] McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014:25;4(8).

[14] Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014 Oct;124(10):4212-8.

[15] Swidsinski A, Loening-Baucke V, Schulz S, et al. Functional anatomy of the colonic bioreactor: Impact of antibiotics and Saccharomyces boulardii on bacterial composition in human fecal cylinders. Syst Appl Microbiol. 2016 Feb;39(1):67-75.

[16] Thomas LV, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr. 2015 Dec;114 Suppl 1:S1-15.

[17] Swidsinski A, Loening-Baucke V, Kirsch S, et al. Functional biostructure of colonic microbiota (central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardii. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S79-92.

[18] Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014 May;39(10):1113-25.

[19] Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014 Feb 19;9(2):e87796.

[20] Collignon A, Sandré C, Barc MC. Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 1:S71-8.

[21] Barc MC, Charrin-Sarnel C, Rochet V, et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe. 2008 Oct;14(4):229-33.

[22] Sassone-Corsi M, Raffatellu M. No Vacancy: How beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol. 2015;194(9):4081–87.

[23] Manley KJ, Fraenkel MB, Mayall BC, et al. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007 May 7;186(9):454-7.

[24] Sassone-Corsi M, Raffatellu M. No Vacancy: How beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol. 2015;194(9):4081–87.

[25] More M, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clinical and Experimental Gastroenterology. 2015;8:237-55.

[26] McFarland LV. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014:25;4(8).

[27] Joshi A, Suja S, Jashbhai P. Identification of Lactobacillus rhamnosus GG bacteriocin gene determinants expressed in vivo in murine gut. World J Food Dairy Sci. 2014:9(1):70-8.

[28] Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis. 2015 May 15;60 Suppl 2:S108-21.